PARIS - Bioptimus announced today the launch of its Spatial Tissue Embedding Learning Atlas (STELA), a multinational data generation initiative in partnership with 10x Genomics, Inc. (NASDAQ:TXG) and Broad Clinical Labs, according to a press release statement. The partnership comes as 10x Genomics shares have surged 103% over the past year, trading at $19.81 with a market capitalization of $2.53 billion.
The initiative aims to profile up to 100,000 patient tissue specimens across the United States, Europe, and Asia. This represents approximately a 20-fold increase in scale over existing spatial biology atlases, the company stated.
STELA will utilize 10x Genomics’ Xenium spatial transcriptomics platform as its foundational technology. The initiative will generate datasets integrating high-resolution spatial transcriptomics, histopathology imaging, multi-omics data including genomics, transcriptomics and proteomics, along with longitudinal clinical records.
The data will support M-Optimus, Bioptimus’ multimodal biological model. Participating hospitals and research institutions will contribute samples under standardized protocols and receive access to spatial characterization and foundation model capabilities.
"STELA is the fuel to power M-Optimus, allowing us to map the intricate interactions between cells and tissues, across indications, at unprecedented scales, unlocking a new era of precision medicine," said Jean Philippe Vert, Co-Founder and CEO of Bioptimus.
Bioptimus will collaborate with Broad Clinical Laboratories through a multi-year agreement to generate spatial biology data. The partnership will leverage Broad’s laboratory workflows to process biological samples and develop AI-driven quality control metrics.
"By enabling spatial profiling at unprecedented scale, STELA will generate foundational datasets that allow researchers to connect the underlying biology with disease outcomes," said Serge Saxonov, Chief Executive Officer of 10x Genomics.
The initiative will focus initially on oncology and immunology tissue samples. Bioptimus stated its models are currently used by 16 of the top 20 pharmaceutical companies.
In other recent news, 10x Genomics reported its fourth-quarter 2025 earnings, surpassing expectations with an earnings per share of -$0.13, compared to the forecasted -$0.22. The company’s revenue reached $166 million, exceeding projections of $157.73 million. Stifel raised its price target for 10x Genomics to $25 from $20, maintaining a Buy rating due to the strong adoption of the company’s new Flex Apex product. Canaccord Genuity also increased its price target to $22 from $20, following the company’s financial results.
Meanwhile, ARK Invest sold over 473,000 shares of 10x Genomics, causing a 12% drop in the stock. This move by Cathie Wood’s firm has raised concerns about potential reductions in holdings by other institutional investors. Additionally, Wolfe Research commented on the potential impact of Microsoft’s new AI model, GigaTIME, on the demand for spatial proteomics, leading to further investor apprehension. These developments highlight the dynamic environment surrounding 10x Genomics, as it navigates both market opportunities and challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.